Sharing clinical trial data on patient level: Opportunities and challenges
Abstract
In recent months one of the most controversially discussed topics among regulatory agencies, the pharmaceutical industry, journal editors, and academia has been the sharing of patient‐level clinical trial data. Several projects have been started such as the European Medicines Agency´s (EMA) “proactive publication of clinical trial data”, the BMJ open data campaign, or the AllTrials initiative. The executive director of the EMA, Dr. Guido Rasi, has recently announced that clinical trial data on patient level will be published from 2014 onwards (although it has since been delayed). The EMA draft policy on proactive access to clinical trial data was published at the end of June 2013 and open for public consultation until the end of September 2013. These initiatives will change the landscape of drug development and publication of medical research. They provide unprecedented opportunities for research and research synthesis, but pose new challenges for regulatory authorities, sponsors, scientific journals, and the public. Besides these general aspects, data sharing also entails intricate biostatistical questions such as problems of multiplicity. An important issue in this respect is the interpretation of multiple statistical analyses, both prospective and retrospective. Expertise in biostatistics is needed to assess the interpretation of such multiple analyses, for example, in the context of regulatory decision‐making by optimizing procedural guidance and sophisticated analysis methods.
Citing Literature
Number of times cited according to CrossRef: 21
- E.E. Grinich, J. Schmitt, D. Küster, P.I. Spuls, H.C. Williams, J.R. Chalmers, K.S. Thomas, C. Apfelbacher, C.A.C. Prinsen, M. Furue, B. Stuart, B. Carter and E.L. Simpson, Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient‐Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative, British Journal of Dermatology, 179, 2, (540-541), (2018).
- T. Jaki, A. Gordon, P. Forster, L. Bijnens, B. Bornkamp, W. Brannath, R. Fontana, M. Gasparini, L.V. Hampson, T. Jacobs, B. Jones, X. Paoletti, M. Posch, A. Titman, R. Vonk and F. Koenig, A proposal for a new PhD level curriculum on quantitative methods for drug development, Pharmaceutical Statistics, 17, 5, (593-606), (2018).
- Tim Friede, Martin Posch, Sarah Zohar, Corinne Alberti, Norbert Benda, Emmanuelle Comets, Simon Day, Alex Dmitrienko, Alexandra Graf, Burak Kürsad Günhan, Siew Wan Hee, Frederike Lentz, Jason Madan, Frank Miller, Thomas Ondra, Michael Pearce, Christian Röver, Artemis Toumazi, Steffen Unkel, Moreno Ursino, Gernot Wassmer and Nigel Stallard, Recent advances in methodology for clinical trials in small populations: the InSPiRe project, Orphanet Journal of Rare Diseases, 10.1186/s13023-018-0919-y, 13, 1, (2018).
- Takuya Kawahara, Musashi Fukuda, Koji Oba, Junichi Sakamoto and Marc Buyse, Meta-analysis of randomized clinical trials in the era of individual patient data sharing, International Journal of Clinical Oncology, 10.1007/s10147-018-1237-z, 23, 3, (403-409), (2018).
- Garrath Williams and Iris Pigeot, Consent and confidentiality in the light of recent demands for data sharing, Biometrical Journal, 59, 2, (240-250), (2016).
- R. M. Lark, Controlling the marginal false discovery rate in inferences from a soil dataset with α‐investment, European Journal of Soil Science, 68, 2, (221-234), (2017).
- Jos Runhaar, Rianne M Rozendaal, Marienke van Middelkoop, Hans J W Bijlsma, Michael Doherty, Krysia S Dziedzic, L Stefan Lohmander, Timothy McAlindon, Weiya Zhang and Sita Bierma Zeinstra, Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank, Annals of the Rheumatic Diseases, 76, 11, (1862), (2017).
- Julie Babyar, Clinical trial design and recommendations: collectively, we can take them, Clinical and Experimental Medicine, (2017).
- Dominic Way, Hortense Blazsin, Ragnar Löfstedt and Frederic Bouder, Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature, Drug Safety, 10.1007/s40264-016-0466-1, 40, 1, (15-36), (2016).
- Olga Gurgula, Monopoly v. Openness: Two sides of IP coin in the pharmaceutical industry, The Journal of World Intellectual Property, 20, 5-6, (206-220), (2017).
- Ralf-Dieter Hilgers, Diane Uschner, William F. Rosenberger and Nicole Heussen, ERDO - a framework to select an appropriate randomization procedure for clinical trials, BMC Medical Research Methodology, 17, 1, (2017).
- Gerald Hlavin, Franz Koenig, Christoph Male, Martin Posch and Peter Bauer, Evidence, eminence and extrapolation, Statistics in Medicine, 35, 13, (2117-2132), (2016).
- Magdalena Espinoza, Antony Hsieh and David Hsiehchen, Systematic characterization of gastrointestinal clinical trials, Digestive and Liver Disease, 48, 5, (480), (2016).
- Gilles Chatellier, Vincent Varlet, Corinne Blachier-Poisson, Nathalie Beslay, Jehan-Michel Behier, David Braunstein, Mireille Caralp, Brigitte Congard-Chassol, Isabelle Diaz, Laure Fournier, Anne Josseran, Philippe Lechat, Cinira Lefevre, Franck von Lennep, Karine Levesque, Philippe Maugendre, Guillaume Marchand, Didier Mennecier, Nicholas Moore, Sophie Ravoire and Christine Riou, « Big data » et « open data » : quel accès pour la recherche ?, Thérapie, 71, 1, (97), (2016).
- Dominic Way, Frederic Bouder, Ragnar Löfstedt and Darrick Evensen, Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients, Journal of Risk Research, 19, 9, (1185), (2016).
- H‐G Eichler, B Bloechl‐Daum, P Bauer, F Bretz, J Brown, LV Hampson, P Honig, M Krams, H Leufkens, R Lim, MM Lumpkin, MJ Murphy, F Pignatti, M Posch, S Schneeweiss, M Trusheim and F Koenig, “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?, Clinical Pharmacology & Therapeutics, 100, 6, (699-712), (2016).
- Gilles Chatellier, Vincent Varlet, Corinne Blachier-Poisson, Nathalie Beslay, Jehan-Michel Behier, David Braunstein, Mireille Caralp, Brigitte Congard-Chassol, Isabelle Diaz, Laure Fournier, Anne Josseran, Philippe Lechat, Cinira Lefevre, Franck von Lennep, Karine Levesque, Philippe Maugendre, Guillaume Marchand, Didier Mennecier, Nicholas Moore, Sophie Ravoire and Christine Riou, “Big data” and “open data”: What kind of access should researchers enjoy?, Thérapie, 71, 1, (107), (2016).
- Iain Hrynaszkiewicz, Varsha Khodiyar, Andrew L. Hufton and Susanna-Assunta Sansone, Publishing descriptions of non-public clinical datasets: proposed guidance for researchers, repositories, editors and funding organisations, Research Integrity and Peer Review, 1, 1, (2016).
- Ivan Kondofersky, Michael Laimighofer, Christoph Kurz, Norbert Krautenbacher, Julia F. Söllner, Philip Dargatz, Hagen Scherb, Donna P. Ankerst and Christiane Fuchs, Three general concepts to improve risk prediction: good data, wisdom of the crowd, recalibration, F1000Research, 10.12688/f1000research.8680.1, 5, (2671), (2016).
- Jorden A. Cummings, Jessica M. Zagrodney, T. Eugene Day and John Z Metcalfe, Impact of Open Data Policies on Consent to Participate in Human Subjects Research: Discrepancies between Participant Action and Reported Concerns, PLOS ONE, 10, 5, (e0125208), (2015). 2015 17th International Conference on E-health Networking, Application & Services (HealthCom) Boston, MA, USA 2015 17th International Conference on E-health Networking, Application & Services (HealthCom) IEEE , (2015). 978-1-4673-8325-7 Eliot Rich, David F. Andersen, William Augustine, Felipe Cronemberger, Katrina Hull, Luis Luna-Reyes, Roderick MacDonald, Mahdi Najafabadi, Smita Sharma, Carson Tao, James P. Houghton, Jack Homer and Xu Jianping An experimental platform for interpreting open-source health data though integration with dynamic disease models and geoplots , (2015). 97 101 7454480 , 10.1109/HealthCom.2015.7454480 http://ieeexplore.ieee.org/document/7454480/
